Glaukos Archives - Page 3 of 3 - Medical Design Sourcing

The 18 most innovative medical devices of 2021

[Images from BD, Edwards, Alcon and CVRx]The Galien Foundation today announced the nominees for most innovative medical devices for its 15th annual Prix Galien USA Awards.

The foundation nominates devices, biotechnology and pharmaceutical products for its annual Prix Galien awards to highlight products designed to improve the human condition.

“The Awards Committee is excited to introduce the nominees for the 2021 Prix Galien USA Awards. These products have been created by scientists who have dedicated their lives to discovering, developing and distributing life-saving answers for patients,” said Sue Desmond-Hellmann, chair of the Prix Galien USA and Prix Galien International Award committees and former CEO of the Bill & Melinda Gates Foundation.

“We appreciate the opportunity to honor these researchers and their tireless efforts,” Desmond-Hellmann said in a news release.

Nominees need to be FDA-approved for the market within the last five years a…

The 18 most innovative medical devices of 2021

[Images from BD, Edwards, Alcon and CVRx]

The Galien Foundation today announced the nominees for most innovative medical devices for its 15th annual Prix Galien USA Awards.

The foundation nominates devices, biotechnology and pharmaceutical products for its annual Prix Galien awards to highlight products designed to improve the human condition.

“The Awards Committee is excited to introduce the nominees for the 2021 Prix Galien USA Awards. These products have been created by scientists who have dedicated their lives to discovering, developing and distributing life-saving answers for patients,” said Sue Desmond-Hellmann, chair of the Prix Galien USA and Prix Galien International Award committees and former CEO of the Bill & Melinda Gates Foundation.

“We appreciate the opportunity to honor these researchers and their tireless efforts,” Desmond-Hellmann said in a news releas…

Glaukos wins Australian regulatory approval for MicroShunt

Glaukos (NYSE:GKOS) recently announced that it received regulatory approval from Australia’s Therapeutic Goods Administration for its Preserflo MicroShunt.

The San Clemente, Calif.-based company designed the MicroShunt to reduce intraocular pressure in the eyes of patients who have primary open-angle glaucoma where IOP remains uncontrollable or where glaucoma progression needs surgery.

Get the full story on our sister site, Medical Tubing + Extrusion.

Glaukos completes enrollment in Phase 3 trials for iDose TR drug-eluting implant

Glaukos (NYSE:GKOS) announced today that it completed enrollment for a Phase 3 clinical program for its iDose TR sustained-release travoprost implant.

San Clemente, Calif.-based Glaukos’ iDose TR implant contains a novel formulation of travoprost, a prostaglandin analog used to reduce intraocular pressure (IOP) through a design that continuously releases therapeutic levels of the medication for at least one year. Once all travoprost is released, the implant can be removed and replaced with a new iDose TR as an alternative to daily eye drop treatment.

Get the full story at our sister site, Drug Delivery Business News.

Glaukos beats The Street in Q1 results

Glaukos (NYSE:GKOS) yesterday posted first-quarter results that beat the overall consensus on Wall Street.

The San Clemente, Calif.-based ophthalmic medical technology company reported losses of -$16.469 million, or -36¢ per share, on sales of $67.968 million for the three months ended March 31, for a sales growth of 22.83% compared with Q1 2020.

Adjusted to exclude one-time items, earnings per share were -21¢, 10¢ ahead of The Street, where analysts were looking for sales of $65.07 million.

“Our strong start to the year reflects our teams’ unwavering commitment to advance our key strategic priorities and execute our plans,” president and CEO Thomas Burns said in a news release. “While we recognize uncertainties associated with COVID-19 may persist, I am encouraged by the continued recovery trends and believe our business prospects remain robust as we advance our mission to transform the treatment of chronic eye diseases for the benefit of patients world…

Glaukos inks licensing deal with Intratus for Eyelid drug delivery platform

Glaukos (NYSE:GKOS) announced today that it entered into a licensing agreement with Intratus over its Eyelid drug delivery platform.

San Clemente, Calif.-based Glaukos was granted a global exclusive license to research, develop, manufacture and commercialize Intratus’ patented, non-invasive Eyelid drug delivery platform for treating presbyopia, according to a news release. Financial terms were not disclosed.

Get the full story at our sister site, Drug Delivery Business News.

The 18 most innovative medical devices of 2020

The Galien Foundation recently announced nominees for most innovative medical devices for its 14th Annual Prix Galien USA Awards.

The foundation bestows the Prix Galien Award annually to examples of outstanding biomedical and technology products that are designed to improve the human condition.

“As we celebrate 50 years of the Prix Galien process, we are honored to announce this year’s Prix Galien USA nominees, which represent the determination and passion for change that serves as the driving force of life-changing innovation,” said Sue Desmond-Hellmann, chair of the Prix Galien USA and Prix Galien International Committees, in a news release. “The awards committee applauds the nominees for their commitment to ensure a healthier future for generations to come.”

Get the full story on our sister site, Medical Design & Outsourcing.

The 18 most innovative medical devices of 2020

The Galien Foundation recently announced nominees for most innovative medical devices for its 14th Annual Prix Galien USA Awards.

The foundation bestows the Prix Galien Award annually to examples of outstanding biomedical and technology products that are designed to improve the human condition.

“As we celebrate 50 years of the Prix Galien process, we are honored to announce this year’s Prix Galien USA nominees, which represent the determination and passion for change that serves as the driving force of life-changing innovation,” said Sue Desmond-Hellmann, chair of the Prix Galien USA and Prix Galien International Committees, in a news release. “The awards committee applauds the nominees for their commitment to ensure a healthier future for generations to come.”

Nominees need to be FDA-approved for the market within the last five years, and show major potential to affect healthcare. The winners will be announced in October th…

Glaukos announces $200m offering

Glaukos (NYSE:GKOS) announced today that it intends to offer convertible senior notes worth $200 million in a private offering.

San Clemente, Calif.-based Glaukos is offering the notes, due in 2027, only to qualified institutional buyers with a 13-day option for initial purchasers to purchase up to an additional $30 million in notes, according to a news release.

In connection with the pricing, the ophthalmic medical technology and pharmaceutical company expects to enter into privately negotiated capped call transactions with one or more initial purchasers and their affiliates. Those transactions cover the number of shares of common stock initially underlying the notes in an effort to reduce potential dilution.

Glaukos plans to use the proceeds to pay the cost of the capped call transactions, with the remainder earmarked for general corporate purposes. If the options are exercised, the company expects to use a portion of those proceeds to enter into addit…